Table 3.
Patient demographics and clinical characteristics by parathyroid hormone level at study entry
| Patient Characteristics | Parathyroid Hormone at DOPPS enrollment (pg/ml)a | |||||
|---|---|---|---|---|---|---|
| <50 | 50–149 | 150–300 | 301–450 | 451–600 | >600 | |
| Patients, n (%) | 4111 (12) | 9770 (27) | 10,340 (29) | 4849 (14) | 2545 (7) | 4040 (11) |
| Age, yr | 64.1±14.1 | 64.7±14.0 | 64.0±14.3 | 62.0±14.9 | 60.5±14.9 | 56.2±15.7 |
| Men | 58.8 | 59.7 | 59.0 | 57.9 | 55.5 | 55.4 |
| Black | 6.3 | 8.2 | 13.4 | 16.7 | 18.3 | 25.2 |
| Body mass index, kg/m2 | 23.6±5.2 | 24.5±5.6 | 25.5±6.0 | 26.2±6.4 | 26.3±6.3 | 26.5±6.7 |
| Time on dialysis, yrb | 2.3 [1.0–4.9] | 2.4 [1.0–5.1] | 2.5 [1.0–5.3] | 2.7 [1.1–5.9] | 3.2 [1.2–6.6] | 4.0 [1.6–7.5] |
| Fistula | 64.8 | 65.0 | 64.8 | 63.9 | 61.9 | 58.4 |
| Graft | 17.6 | 16.5 | 16.0 | 16.8 | 16.3 | 18.7 |
| Catheter | 16.9 | 17.9 | 18.6 | 19.0 | 21.4 | 22.2 |
| Diabetes | 39.2 | 41.6 | 43.9 | 42.9 | 38.7 | 32.6 |
| Coronary artery disease | 35.0 | 36.0 | 37.8 | 36.8 | 33.0 | 28.0 |
| Congestive heart failure | 32.2 | 32.9 | 32.4 | 32.1 | 33.9 | 30.9 |
| Cerebrovascular disease | 18.7 | 18.1 | 15.9 | 15.0 | 14.4 | 11.7 |
| Peripheral arterial disease | 27.5 | 27.5 | 27.1 | 25.4 | 25.3 | 20.1 |
| Hypertension | 78.0 | 79.6 | 80.8 | 80.3 | 80.5 | 79.5 |
| Other cardiovascular disease | 34.9 | 34.5 | 32.2 | 30.3 | 30.9 | 27.6 |
| Recurrent cellulitis | 8.8 | 9.0 | 9.0 | 9.1 | 9.7 | 7.3 |
| Cancer (other than skin) | 11.4 | 12.8 | 11.9 | 10.5 | 10.5 | 8.6 |
| Gastrointestinal bleeding | 6.9 | 6.2 | 5.0 | 5.5 | 5.6 | 4.3 |
| Lung disease | 10.7 | 12.3 | 12.1 | 11.9 | 11.8 | 10.7 |
| Neurologic disease | 10.9 | 10.9 | 10.2 | 9.7 | 9.8 | 10.2 |
| Psychiatric disorder | 16.3 | 16.9 | 15.6 | 16.9 | 18.3 | 18.3 |
| Hemoglobin, g/dl | 10.9±1.5 | 11.2±1.5 | 11.3±1.5 | 11.3±1.5 | 11.3±1.5 | 11.3±1.6 |
| Serum albumin, g/dl | 3.7±0.5 | 3.7±0.5 | 3.8±0.5 | 3.8±0.4 | 3.8±0.5 | 3.8±0.5 |
| Serum creatinine, mg/dl | 8.9±3.1 | 8.7±3.1 | 8.7±3.1 | 9.0±3.1 | 9.3±3.0 | 9.9±3.3 |
| Serum calcium, mg/dl | 9.5±0.9 | 9.2±0.8 | 9.1±0.8 | 9.1±0.9 | 9.1±0.9 | 9.2±0.9 |
| Serum phosphorus, mg/dl | 5.2±1.7 | 5.2±1.6 | 5.3±1.6 | 5.6±1.7 | 5.8±1.7 | 6.2±1.9 |
| Phosphate binder (any)c | 84.6 | 82.6 | 83.2 | 84.4 | 85.0 | 85.7 |
| Phosphate binder (calcium-based) | 68.5 | 61.3 | 54.5 | 51.6 | 48.6 | 45.9 |
| Phosphate binder (noncalcium-based) | 19.0 | 25.9 | 34.7 | 40.0 | 43.9 | 49.1 |
| Vitamin D analog (i.v. or oral)d | 40.1 | 42.8 | 56.1 | 64.4 | 66.4 | 63.4 |
| Vitamin D analog (i.v.)d | 7.9 | 17.1 | 33.3 | 41.8 | 42.4 | 41.5 |
| Vitamin D analog (oral)d | 30.2 | 26.4 | 25.2 | 25.5 | 28.4 | 24.3 |
| Cinacalcete | 1.4 | 3.7 | 6.5 | 10.2 | 12.9 | 18.7 |
| Untreated patients | 34.1 | 28.2 | 17.2 | 11.2 | 9.1 | 7.7 |
Data are shown as mean±SD or percentage. All patient characteristics as reported at entry into the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Parathyroid hormone values were on the basis of the first nonmissing values within 1 year since baseline.
Median [interquartile range].
Includes calcium-based, noncalcium-based, or both. Type of phosphate binder (calcium-based or noncalcium-based) was not available in DOPPS phase 1.
Includes calcitriol, doxercalciferol, paricalcitol, maxacalcitol, alphacalcidol, and falecalsitol. Type of vitamin D (i.v. or oral) was not available in DOPPS phase 1.
Cinacalcet was available in clinical practice in DOPPS phases 3 and 4 only.